CRISPR

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade CRISPR 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. 

CEO
Samarth Kulkarni
CEOSamarth Kulkarni
Employees
393
Employees393
Headquarters
Zug, Zug
HeadquartersZug, Zug
Founded
2013
Founded2013
Employees
393
Employees393

CRSP Key Statistics

Market cap
4.69B
Market cap4.69B
Price-Earnings ratio
-7.66
Price-Earnings ratio-7.66
Dividend yield
Dividend yield
Average volume
2.91M
Average volume2.91M
High today
$50.05
High today$50.05
Low today
$48.20
Low today$48.20
Open price
$49.09
Open price$49.09
Volume
3.29M
Volume3.29M
52 Week high
$78.48
52 Week high$78.48
52 Week low
$30.04
52 Week low$30.04

Stock Snapshot

With a market cap of 4.69B, CRISPR(CRSP) trades at $48.75. The stock has a price-to-earnings ratio of -7.66.

On 2026-03-12, CRISPR(CRSP) stock traded between a low of $48.20 and a high of $50.05. Shares are currently priced at $48.75, which is +1.1% above the low and -2.6% below the high.

The CRISPR(CRSP)'s current trading volume is 3.29M, compared to an average daily volume of 2.91M.

In the last year, CRISPR(CRSP) shares hit a 52-week high of $78.48 and a 52-week low of $30.04.

In the last year, CRISPR(CRSP) shares hit a 52-week high of $78.48 and a 52-week low of $30.04.

CRSP News

Nasdaq 1d
CRISPR Therapeutics Announces Pricing Of $550 Mln Of Convertible Senior Notes Offering

(RTTNews) - CRISPR Therapeutics AG (CRSP), Wednesday announced the pricing of $550 million of its convertible senior notes due 2031 in a private offering to per...

CRISPR Therapeutics Announces Pricing Of $550 Mln Of Convertible Senior Notes Offering
TipRanks 2d
Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million

An update from Crispr Therapeutics AG ( (CRSP) ) is now available. On March 10, 2026, CRISPR Therapeutics AG announced plans to privately offer $350 million of...

Simply Wall St 7d
Casgevy Uptake Grows As CRISPR Therapeutics Shares Trade Below Estimates

CRISPR Therapeutics reported a threefold increase in Casgevy patient initiations for sickle cell disease and beta thalassemia over the past year. The company h...

Casgevy Uptake Grows As CRISPR Therapeutics Shares Trade Below Estimates

Analyst ratings

59%

of 29 ratings
Buy
58.6%
Hold
37.9%
Sell
3.4%

People also own

Based on the portfolios of people who own CRSP. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.